ACW 3.45% 9.0¢ actinogen medical limited

11βHSD1 inhibitor use in human disease- a systematic review and narrative synthesis, page-62

  1. 48 Posts.
    lightbulb Created with Sketch. 2
    But I am speaking about the science with regards to the tests used -
    The test used is a behavioral test, whereas neuroscience has many better investigation techniques that have been standard for the last 25 years:
    For example, the effects of Xanamem on long term potentiation (LTP) in the hippocampus would be the standard test for investigation of a new drug compound and its action(s) on cellular memory - this work seems to be missing.
    Occupancy studies & binding to 11-beta-HSD-1 cortisol-activation enzyme have no direct link to memory.
    I am hoping for some sophisticated science to put a link between Xanamem treatment and its impact on memory beyond the cited behavioural tests : )
 
watchlist Created with Sketch. Add ACW (ASX) to my watchlist
(20min delay)
Last
9.0¢
Change
0.003(3.45%)
Mkt cap ! $261.3M
Open High Low Value Volume
8.7¢ 9.9¢ 8.5¢ $2.173M 23.37M

Buyers (Bids)

No. Vol. Price($)
1 15000 9.1¢
 

Sellers (Offers)

Price($) Vol. No.
9.2¢ 48145 3
View Market Depth
Last trade - 15.57pm 18/07/2024 (20 minute delay) ?
ACW (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.